Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 2-Pyrrolidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.75 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.64 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Pyrrolidone SCHEMBL6929736 | 0.97 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL353224 | 0.97 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL14977810 | 0.97 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL14977562 | 0.97 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL2708992 | 0.95 | OR51E2 (0.75) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL22749298 | 0.95 | OR51E2 (0.75) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL4655461 | 0.92 | OR51E2 (0.88) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL3356160 | 0.92 | — | — | |
| Caprolactam SCHEMBL17961671 | 0.91 | CRBN (0.73) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL28124617 | 0.91 | OR51E2 (0.68) | OR51E2CRBNFKBP5KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11298307-B2 | Transparent or semitransparent cosmetic composition having enhanced amentoflavone stability | AMOREPACIFIC CORPORATION (KR) | 2022-04-12 | — | — | US | claimed |
| WO-2020245569-A1 | SKIN TREATMENT COMPOSITION | Boston Healthcare Limited (GB) | 2020-12-10 | — | — | WO | claimed |
| US-20200054540-A1 | TRANSPARENT OR SEMITRANSPARENT COSMETIC COMPOSITION HAVING ENHANCED AMENTOFLAVONE STABILITY | AMOREPACIFIC CORPORATION (KR) | 2020-02-20 | — | — | US | claimed |
| CN-110475538-A | Improve the transparent or semitransparent cosmetic composition of amentoflavone stability | AMOREPACIFIC CORP | 2019-11-19 | — | — | CN | claimed |
| US-20180169002-A1 | Skin Rejuvenation and Defense Systems and Methods | CERBERUS BUSINESS FINANCE AGENCY, LLC, AS THE COLLATERAL AGENT | 2018-06-21 | — | — | US | claimed |
| US-9925137-B2 | Skin rejuvenation and defense system | Maple Mountain Group, Inc. (US) | 2018-03-27 | — | — | US | claimed |
| US-20170049692-A1 | SKIN REJUVENATION AND DEFENSE SYSTEM | CERBERUS BUSINESS FINANCE AGENCY, LLC, AS THE COLLATERAL AGENT | 2017-02-23 | — | — | US | claimed |
| US-5702691-A | Flavanonol derivatives and hair-nourishing, hair growing compositions containing the derivatives | KAO CORPORATION (JP) | 1997-12-30 | — | — | US | claimed |
| US-4151269-A | ETHYLENE OXIDE, PROPYLENE OXIDE, POLYOL, POLYETHERS | SHISEIDO CO., LTD. (JP) | 1979-04-24 | — | — | US | claimed |
| EP-4684011-A1 | METHOD FOR ISOLATING NUCLEIC ACID FROM A BIOLOGICAL SAMPLE | Bioecho Life Sciences GmbH (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250277207-A1 | One or Multiple-Steps Extraction of Nucleic Acids and other Biomolecules using a Cloudy Precipitated Solution | CHHALLIYIL PRADHEEP (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2024194332-A1 | METHOD FOR ISOLATING NUCLEIC ACID FROM A BIOLOGICAL SAMPLE | BIOECHO LIFE SCIENCES GMBH (DE) | 2024-09-26 | — | — | WO | disclosed |
| EP-3873418-B1 | ACTIVE INGREDIENT COMPOSITION FOR THE CARE OF HUMAN HAIR | HENKEL AG & CO KGAA (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | AUBURN UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| EP-0743311-A1 | FLAVANONOL DERIVATIVES AND HAIR NOURISHMENT AND GROWTH STIMULANT COMPOSITION CONTAINING THE SAME | Kao Corporation (JP) | 1996-11-20 | — | — | EP | disclosed |
| EP-0665004-A2 | An antimicrobial cosmetic pigment, its production process, and a cosmetic containing it | LUCKY LTD. (KR) | 1995-08-02 | — | — | EP | disclosed |
| US-4536324-A | Nonionic surfactant type vesicle dispersion | LION CORPORATION (JP) | 1985-08-20 | — | — | US | disclosed |
| US-4309447-A | HYDROXYPROPYL-ETHERIFIED GLYCOLIPID ESTER | KAO SOAP CO., LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| US-4305961-A | HYDROXYALKYL-ETHERIFIED GLYCOLIPID ESTER | KAO SOAP CO., LTD. (JP) | 1981-12-15 | — | — | US | disclosed |
| US-4151269-A | ETHYLENE OXIDE, PROPYLENE OXIDE, POLYOL, POLYETHERS | SHISEIDO CO., LTD. (JP) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | NSFL1C, SOD1, CLTC | OR51E2 3200/4885CRBN 232/4885FKBP5 2281/4885 |
| US-11298307-B2 | Transparent or semitransparent cosmetic composition having enhanced amentoflavone stability | TEAD2, FANCF, TEAD4 | OR51E2 449/4885CRBN 3801/4885FKBP5 3138/4885 |
| US-20200054540-A1 | TRANSPARENT OR SEMITRANSPARENT COSMETIC COMPOSITION HAVING ENHANCED AMENTOFLAVONE STABILITY | TEAD2, FANCF, TEAD4 | OR51E2 449/4885CRBN 3801/4885FKBP5 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.